Johnson & Johnson Calls It Quits on Insulin Pumps Business
Customers currently using Animas insulin pumps will be offered the option to transfer to a pump from Medtronic.

Johnson & Johnson's (JNJ) Animas Corp. will close operations and exit the insulin pump market in the U.S. and Canada, the company said in a statement, effective immediately.

"With changing needs of customers, rapidly evolving market dynamics and increased competitive pressures, it proved too difficult to sustain the insulin pump business," J&J wrote.

Customers currently using Animas insulin pumps will be offered the option to transfer to a pump from Medtronic plc (MDT) , which Animas chose as its partner for existing users throughout the process of shuttering its business. Animas manufactured and sold the Animas Vibe and OneTouch Ping pumps.

About 90,000 patients currently use Animas products and pumps, and the company employs 410 people globally. Products sold and manufactured by Animas in countries other than the U.S. and Canada will continue with normal operations.

J&J stock fell 0.13% to $132.72 in midday trading Thursday.

More of What's Trending on TheStreet:

More from Stocks

A Guide to Investing in the Fast-Emerging Cannabis Industry

A Guide to Investing in the Fast-Emerging Cannabis Industry

Chart of the Day: Can Disney Catch Netflix?

Chart of the Day: Can Disney Catch Netflix?

Dow Surges More Than 540 Points on Strong Bank Earnings; Nasdaq Gains 2.9%

Dow Surges More Than 540 Points on Strong Bank Earnings; Nasdaq Gains 2.9%

Analysts Confident Netflix Can Restore Content Crown in 2019

Analysts Confident Netflix Can Restore Content Crown in 2019

UnitedHealth Group: A Steady Performer With Room to Run

UnitedHealth Group: A Steady Performer With Room to Run